Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

This study has been terminated.

(The study was closed due to poor enrollment)

Sponsor:

Collaborators:

Cell Therapeutics

Celgene Corporation

Information provided by (Responsible Party):

Jonsson Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT00234000

First received: October 5, 2005

Last updated: August 2, 2012

Last verified: August 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)